Analyst says these are the 'critical' next steps for Eli Lilly
Feb 6, 2024 · Evan Seigerman, BMO Capital Markets Managing Director joins Yahoo Finance Live, saying he continues to be "surprised at the demand" for these drugs. Seigerman says Eli …
GLP-1 demand is going to remain higher than supply for ... - CNBC
Sep 24, 2024 · Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Schrodinger’s Promising Growth Potential ... - Markets Insider
3 days ago · In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a price target of $28.00. Evan …
Pfizer’s Stock Buy Rating: Undervalued with Growth Potential and ...
Oct 7, 2024 · Evan Seigerman has given his Buy rating due to a combination of factors indicating that Pfizer’s stock is undervalued compared to its U.S. BioPharma peers. His analysis …
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline …
Mar 11, 2024 · Seigerman’s optimism stems from the company’s diverse pipeline, particularly its advancements in obesity and diabetes treatment with GSBR-1290, an oral agent poised to …
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound drugs …
Apr 30, 2024 · Evan Seigerman, an analyst at BMO Capital Markets, said in a note that “the majority of this miss was due to a lack of supply, with Lilly likely shifting capacity to Zepbound …
Merck signs up to $3.3 billion cancer drug deal with China-based …
1 day ago · Latest News. Stock Market. ... BMO analyst Evan Seigerman said the LaNova deal offers a hedge to Merck after the data shown by Summit and others. ... with a wall of clinical …
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales ... - BioSpace
Nov 7, 2024 · BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and “steady,” while noting the company continues to …
The best biotech plays outside the GLP-1 weight-loss market
Sep 19, 2024 · BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 …
Gardasil Chinese Distribution Issue Still a Mystery to Analysts
Aug 7, 2024 · “I think the shocking thing was the level of uncertainty,” Evan Seigerman, managing director and senior research analyst at Bank of Montreal Capital Markets, told BioSpace. …